Methimazole - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (1)Enzymes (8)

Targets (1)Enzymes (8)Biointeractions (9)

Identification

Name

Methimazole

Accession Number

DB00763 (APRD00002)

Type

Small Molecule

Groups

Approved

Description

A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme. [PubChem]

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

1-METHYL-1,3-dihydro-2H-imidazole-2-thione

1-Methylimidazole-2(3H)-thione

Danantizol

Favistan

Mercazolyl

Methimazole

Strumazol

Tapazole

Thacapzol

Thiamazol

Thiamazole

Thiamazolum

Tiamazol

USAF el-30

External IDs

NSC 38608 / UNII-554Z48XN5E

Product Ingredients

Not Available

Product Images

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Dom-methimazole	Tablet	5 mg	Oral	Dominion Pharmacal	Not applicable	Not applicable	Canada
PHL-methimazole	Tablet	5 mg	Oral	Pharmel Inc	Not applicable	Not applicable	Canada
PMS-methimazole	Tablet	5 mg	Oral	Pharmascience Inc	2004-11-05	2005-05-04	Canada
Tapazole	Tablet	10 mg	Oral	Paladin Labs Inc	2008-01-07	Not applicable	Canada
Tapazole	Tablet	20 mg	Oral	Paladin Labs Inc	Not applicable	Not applicable	Canada
Tapazole 5mg Tablet	Tablet	5 mg	Oral	Paladin Labs Inc	1951-12-31	Not applicable	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-methimazole	Tablet	5 mg	Oral	Apotex Corporation	2005-03-18	Not applicable	Canada
Methimazole	Tablet	10 mg/1	Oral	Par Pharmaceutical	2000-04-13	Not applicable	US
Methimazole	Tablet	5 mg/1	Oral	Eon Labs, Inc.	2001-03-27	Not applicable	US
Methimazole	Tablet	5 mg/1	Oral	Rising Pharmaceuticals	2015-09-28	Not applicable	US
Methimazole	Tablet	10 mg/1	Oral	Remedy Repack	2013-07-02	Not applicable	US
Methimazole	Tablet	10 mg/1	Oral	Rebel Distributors	2010-07-07	Not applicable	US
Methimazole	Tablet	10 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2001-03-27	Not applicable	US
Methimazole	Tablet	10 mg/1	Oral	State of Florida DOH Central Pharmacy	2014-01-01	Not applicable	US
Methimazole	Tablet	5 mg/1	Oral	Amerincan Health Packaging	2013-06-14	Not applicable	US
Methimazole	Tablet	5 mg/1	Oral	Eci Pharmaceuticals Llc	2016-07-01	Not applicable	US
Methimazole	Tablet	10 mg/1	Oral	Remedy Repack	2011-11-01	2016-11-05	US
Methimazole	Tablet	10 mg/1	Oral	Boca Pharmacal, Inc.	2012-03-07	2017-02-28	US
Methimazole	Tablet	10 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2014-02-27	Not applicable	US
Methimazole	Tablet	10 mg/1	Oral	Remedy Repack	2013-03-18	2016-10-21	US
Methimazole	Tablet	5 mg/1	Oral	Golden State Medical Supply	2013-01-08	Not applicable	US
Methimazole	Tablet	5 mg/1	Oral	Exact Rx, Inc.	2012-01-12	Not applicable	US
Methimazole	Tablet	5 mg/1	Oral	Remedy Repack	2013-11-12	Not applicable	US
Methimazole	Tablet	10 mg/1	Oral	Eon Labs, Inc.	2001-03-27	Not applicable	US
Methimazole	Tablet	10 mg/1	Oral	Rising Pharmaceuticals	2015-09-28	Not applicable	US
Methimazole	Tablet	10 mg/1	Oral	bryant ranch prepack	2000-04-13	Not applicable	US
Methimazole	Tablet	5 mg/1	Oral	Heritage	2012-01-16	Not applicable	US
Methimazole	Tablet	10 mg/1	Oral	State of Florida DOH Central Pharmacy	2014-01-01	Not applicable	US
Methimazole	Tablet	10 mg/1	Oral	Amerincan Health Packaging	2013-06-14	Not applicable	US
Methimazole	Tablet	10 mg/1	Oral	Eci Pharmaceuticals Llc	2016-07-01	Not applicable	US
Methimazole	Tablet	5 mg/1	Oral	Rebel Distributors	2010-07-07	Not applicable	US
Methimazole	Tablet	10 mg/1	Oral	Golden State Medical Supply	2013-01-08	Not applicable	US
Methimazole	Tablet	5 mg/1	Oral	Par Pharmaceutical	2012-02-28	Not applicable	US
Methimazole	Tablet	10 mg/1	Oral	State of Florida DOH Central Pharmacy	2013-01-01	Not applicable	US
Methimazole	Tablet	10 mg/1	Oral	Dispensing Solutions, Inc.	2012-01-16	Not applicable	US
Methimazole	Tablet	10 mg/1	Oral	Unit Dose Services	2001-03-27	Not applicable	US
Methimazole	Tablet	10 mg/1	Oral	Exact Rx, Inc.	2012-01-12	Not applicable	US
Methimazole	Tablet	5 mg/1	Oral	Boca Pharmacal, Inc.	2012-03-07	2017-01-31	US
Methimazole	Tablet	5 mg/1	Oral	A S Medication Solutions	2012-02-28	2017-06-20	US
Methimazole	Tablet	5 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2001-03-27	Not applicable	US
Methimazole	Tablet	10 mg/1	Oral	Heritage	2012-01-16	Not applicable	US
Methimazole	Tablet	5 mg/1	Oral	Physicians Total Care, Inc.	2009-10-13	Not applicable	US
Methimazole	Tablet	5 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2015-10-06	Not applicable	US
Methimazole	Tablet	10 mg/1	Oral	bryant ranch prepack	2000-04-13	Not applicable	US
Tapazole	Tablet	5 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc.	2000-03-31	Not applicable	US
Tapazole	Tablet	5 mg/1	Oral	Remedy Repack	2013-02-18	2016-12-23	US
Tapazole	Tablet	10 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc.	2000-03-31	Not applicable	US
Tapazole	Tablet	10 mg/1	Oral	Remedy Repack	2013-03-13	2017-01-11	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Danantizol	Gador S.A.
Favistan	Temmler
Metizol	ICN
Strumazol	Organon
Strumazole	Not Available
Thacapzol	Recip
Thycapzol	Sandoz
Thyrozol	Merck
Tirozol	Merck

Brand mixtures

Not Available

Categories

UNII

554Z48XN5E

CAS number

60-56-0

Weight

Average: 114.169
Monoisotopic: 114.025168892

Chemical Formula

C₄H₆N₂S

InChI Key

PMRYVIKBURPHAH-UHFFFAOYSA-N

InChI

InChI=1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)

IUPAC Name

1-methyl-2,3-dihydro-1H-imidazole-2-thione

SMILES

CN1C=CNC1=S

Pharmacology

Indication

For the treatment of hyperthyroidism, goiter, Graves disease and psoriasis.

Structured Indications

Pharmacodynamics

Used in the treatment of hyperthyroidism or an overactive thyroid gland, methimazole inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. It may also be used to ameliorate hyperthyroidism in preparation for subtotal thyroidectomy or radioactive iodine therapy.

Mechanism of action

Methimazole binds to thyroid peroxidase and thereby inhibits the conversion of iodide to iodine. Thyroid peroxidase normally converts iodide to iodine (via hydrogen peroxide as a cofactor) and also catalyzes the incorporation of the resulting iodide molecule onto both the 3 and/or 5 positions of the phenol rings of tyrosines found in thyroglobulin. Thyroglobulin is degraded to produce thyroxine (T4) and tri-iodothyronine (T3), which are the main hormones produced by the thyroid gland. So methimazole effectively inhibits the production of new thyroid hormones.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Thyroid peroxidase	Protein	yes	inhibitor	Human	P07202	details

Absorption

Rapid with an oral bioavailability of 93%.

Volume of distribution

Not Available

Protein binding

None or minimal

Metabolism

Primarily hepatic. Metabolized rapidly, requiring frequent administration.

Route of elimination

Methimazole is excreted in the urine.

Half life

5-6 hours

Clearance

Not Available

Toxicity

Oral LD₅₀ in rats is 2250 mg/kg. Symptoms of overdose include nausea, vomiting, epigastric distress, headache, fever, joint pain, pruritus, and edema. Aplastic anemia (pancy-topenia) or agranulocytosis may be manifested in hours to days. Less frequent events are hepatitis, nephrotic syndrome, exfoliative dermatitis, neuropathies, and CNS stimulation or depression.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
Acenocoumarol	Methimazole may decrease the anticoagulant activities of Acenocoumarol.	Approved
Acetyldigitoxin	The serum concentration of Acetyldigitoxin can be increased when it is combined with Methimazole.	Approved
Ambroxol acefyllinate	The serum concentration of Ambroxol acefyllinate can be increased when it is combined with Methimazole.	Experimental
Aminophylline	The serum concentration of Aminophylline can be increased when it is combined with Methimazole.	Approved
Aripiprazole	The serum concentration of Aripiprazole can be increased when it is combined with Methimazole.	Approved, Investigational
Artesunate	The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Methimazole resulting in a loss in efficacy.	Approved
BCG vaccine	The therapeutic efficacy of Bcg can be decreased when used in combination with Methimazole.	Investigational
Cilostazol	The serum concentration of Cilostazol can be increased when it is combined with Methimazole.	Approved
Clozapine	The risk or severity of adverse effects can be increased when Methimazole is combined with Clozapine.	Approved
Deslanoside	The serum concentration of Deslanoside can be increased when it is combined with Methimazole.	Approved
Dicoumarol	Methimazole may decrease the anticoagulant activities of Dicoumarol.	Approved
Digitoxin	The serum concentration of Digitoxin can be increased when it is combined with Methimazole.	Approved
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Methimazole.	Approved
Dyphylline	The serum concentration of Dyphylline can be increased when it is combined with Methimazole.	Approved
Ethyl biscoumacetate	Methimazole may decrease the anticoagulant activities of Ethyl biscoumacetate.	Withdrawn
Fesoterodine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methimazole.	Approved
Fluindione	Methimazole may decrease the anticoagulant activities of Fluindione.	Investigational
Iodide I-131	The therapeutic efficacy of Sodium Iodide I-131 can be decreased when used in combination with Methimazole.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with Methimazole.	Withdrawn
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Methimazole.	Approved, Investigational
Oleandrin	The serum concentration of Anvirzel can be increased when it is combined with Methimazole.	Experimental
Ouabain	The serum concentration of Ouabain can be increased when it is combined with Methimazole.	Approved
Phenindione	Methimazole may decrease the anticoagulant activities of Phenindione.	Approved
Phenprocoumon	Methimazole may decrease the anticoagulant activities of Phenprocoumon.	Approved
Prednisolone	The serum concentration of Prednisolone can be decreased when it is combined with Methimazole.	Approved, Vet Approved
Theophylline	The serum concentration of Theophylline can be increased when it is combined with Methimazole.	Approved
Thioridazine	The serum concentration of Thioridazine can be increased when it is combined with Methimazole.	Withdrawn
Tizanidine	The serum concentration of Tizanidine can be increased when it is combined with Methimazole.	Approved
Warfarin	Methimazole may decrease the anticoagulant activities of Warfarin.	Approved

Food Interactions

Always take at the same moment in regard to meals, food may affect absorption unpredictably.

References

Synthesis Reference

Not Available

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14901
KEGG Drug	D00401
KEGG Compound	C07190
PubChem Compound	1349907
PubChem Substance	46506536
ChemSpider	1131173
BindingDB	50241361
ChEBI	50673
ChEMBL	CHEMBL1515
Therapeutic Targets Database	DNC001429
PharmGKB	PA450422
HET	MMZ
Drug Product Database	14593
RxList	http://www.rxlist.com/cgi/generic3/methim.htm
Drugs.com	http://www.drugs.com/cdi/methimazole.html
Wikipedia	Methimazole

ATC Codes

H03BB02 — Thiamazole

H03BB52 — Thiamazole, combinations

AHFS Codes

68:36.08

PDB Entries

Not Available

FDA label

Not Available

MSDS

Download (75.8 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1, 2	Completed	Treatment	Graves´ Disease / Thyroid Associated Ophthalmopathy	1
2	Completed	Treatment	Dermatomyositis / Polymyositis	1
2	Suspended	Supportive Care	Glioblastoma Multiforme (GBM)	1
3	Recruiting	Treatment	Graves Diseases / Graves Ophthalmopathy / Graves' Ophthalmopathy Worsened	1
4	Completed	Prevention	Graves´ Disease	1
4	Completed	Treatment	Graves Diseases / Toxic Nodular Goitre	1
4	Completed	Treatment	Graves' Disease / Toxic Nodular Goitre	1
4	Unknown Status	Diagnostic	Healthy Volunteers	1
Not Available	Completed	Not Available	Graves Diseases	1
Not Available	Completed	Treatment	Graves Diseases	1
Not Available	Completed	Treatment	Graves' Disease	1
Not Available	Terminated	Treatment	Graves Ophthalmopathy	1

Pharmacoeconomics

Manufacturers

Actavis totowa llc
Caraco pharmaceutical laboratories ltd
Cedar pharmaceuticals llc
Mylan pharmaceuticals inc
Sandoz inc
King pharmaceuticals inc
King pharmaceuticals research and development inc sub king pharmaceuticals inc

Packagers

AAIPharma Inc.
Actavis Group
Amerisource Health Services Corp.
Caraco Pharmaceutical Labs
Cedar Pharmaceuticals LLC
Centrix Pharmaceuticals
Dispensing Solutions
Eon Labs
Heartland Repack Services LLC
Kaiser Foundation Hospital
King Pharmaceuticals Inc.
Medisca Inc.
Mikart Inc.
Murfreesboro Pharmaceutical Nursing Supply
Mylan
Nucare Pharmaceuticals Inc.
Par Pharmaceuticals
Philopharm GmbH
Physicians Total Care Inc.
Remedy Repack
Resource Optimization and Innovation LLC
Southwood Pharmaceuticals
United Research Laboratories Inc.
Vangard Labs Inc.

Dosage forms

Form	Route	Strength
Tablet	Oral	5 mg
Tablet	Oral	10 mg/1
Tablet	Oral	5 mg/1
Tablet	Oral	10 mg
Tablet	Oral	20 mg

Prices

Unit description	Cost	Unit
Methimazole powder	9.49USD	g
Methimazole 20 mg tablet	1.9USD	tablet
Tapazole 10 mg tablet	1.45USD	tablet
Northyx 20 mg tablet	0.94USD	tablet
Northyx 15 mg tablet	0.82USD	tablet
Methimazole 10 mg tablet	0.78USD	tablet
Tapazole 5 mg tablet	0.66USD	tablet
Northyx 10 mg tablet	0.47USD	tablet
Methimazole 5 mg tablet	0.45USD	tablet
Northyx 5 mg tablet	0.29USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	146 °C	PhysProp
boiling point (°C)	280 °C	PhysProp
water solubility	275 g/L	Not Available
logP	-0.34	HANSCH,C ET AL. (1995)

Predicted Properties

Property	Value	Source
Water Solubility	11.3 mg/mL	ALOGPS
logP	-0.38	ALOGPS
logP	0.75	ChemAxon
logS	-1	ALOGPS
pKa (Strongest Acidic)	10.41	ChemAxon
pKa (Strongest Basic)	-3	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	0	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	15.27 Å²	ChemAxon
Rotatable Bond Count	0	ChemAxon
Refractivity	33.23 m³·mol^-1	ChemAxon
Polarizability	11.64 Å³	ChemAxon
Number of Rings	1	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9156
Blood Brain Barrier	+	0.9731
Caco-2 permeable	+	0.6156
P-glycoprotein substrate	Non-substrate	0.8213
P-glycoprotein inhibitor I	Non-inhibitor	0.7552
P-glycoprotein inhibitor II	Non-inhibitor	0.944
Renal organic cation transporter	Non-inhibitor	0.7662
CYP450 2C9 substrate	Non-substrate	0.7919
CYP450 2D6 substrate	Non-substrate	0.8985
CYP450 3A4 substrate	Non-substrate	0.7849
CYP450 1A2 substrate	Non-inhibitor	0.9045
CYP450 2C9 inhibitor	Non-inhibitor	0.9071
CYP450 2D6 inhibitor	Non-inhibitor	0.9232
CYP450 2C19 inhibitor	Non-inhibitor	0.9025
CYP450 3A4 inhibitor	Non-inhibitor	0.8309
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.7105
Ames test	Non AMES toxic	0.8582
Carcinogenicity	Non-carcinogens	0.9348
Biodegradation	Not ready biodegradable	0.9815
Rat acute toxicity	1.8215 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9401
hERG inhibition (predictor II)	Non-inhibitor	0.8416

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Download (8.12 KB)

Spectra

Spectrum Type	Description	Splash Key
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-066r-8900000000-9230df83b87c13377bfb	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-014i-0900000000-275f9771b8d1d7486052	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-014i-0900000000-1763fdc1a812fa765250	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-014i-0900000000-78877e6d65fda61a0e67	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ , positive	splash10-014i-1900000000-c979e7cdbceb656b6a1e	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ , positive	splash10-014i-1900000000-1447e5774eda5dc3fe26	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ , positive	splash10-066r-9300000000-41d253a513ee17fed774	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ , positive	splash10-0a4i-9000000000-11684a341cebaa28c427	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ , positive	splash10-0a60-9000000000-7637560408e70990bc27	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	splash10-014i-0900000000-810e7a010dd805f3251d	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	splash10-014i-5900000000-e88140069cbfa61f9c51	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	splash10-0006-9000000000-3969b3a3102e9214d562	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	splash10-03di-0900000000-3e543dd0166f52789fcd	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	splash10-0900-9300000000-90c58541a936c6fdd275	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	splash10-0a4i-9000000000-9a1c61f319838c2ebce9	View in MoNA

Taxonomy

Description

This compound belongs to the class of chemical entities known as imidazolethiones. These are aromatic compounds containing an imidazole ring which bears a thioketone group.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organoheterocyclic compounds

Sub Class

Azolines

Direct Parent

Imidazolethiones

Alternative Parents

N-substituted imidazoles / Heteroaromatic compounds / Thioureas / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives

Substituents

N-substituted imidazole / Imidazole-2-thione / Heteroaromatic compound / Imidazole / Azole / Thiourea / Azacycle / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

imidazoles, thioureas (CHEBI:50673 ) / a small molecule (CPD-11282 )

Targets

Details

1. Thyroid peroxidase

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Peroxidase activity
Specific Function:: Iodination and coupling of the hormonogenic tyrosines in thyroglobulin to yield the thyroid hormones T(3) and T(4).
Gene Name:: TPO
Uniprot ID:: P07202
Molecular Weight:: 102961.63 Da

References

Sugawara M, Sugawara Y, Wen K: Methimazole and propylthiouracil increase cellular thyroid peroxidase activity and thyroid peroxidase mRNA in cultured porcine thyroid follicles. Thyroid. 1999 May;9(5):513-8. [PubMed:10365684 ]
Manzon RG, Holmes JA, Youson JH: Variable effects of goitrogens in inducing precocious metamorphosis in sea lampreys (Petromyzon marinus). J Exp Zool. 2001 Apr 15;289(5):290-303. [PubMed:11241400 ]
Ferreira AC, de Carvalho Cardoso L, Rosenthal D, de Carvalho DP: Thyroid Ca2+/NADPH-dependent H2O2 generation is partially inhibited by propylthiouracil and methimazole. Eur J Biochem. 2003 Jun;270(11):2363-8. [PubMed:12755690 ]
Magnusson RP, Yu B, Brennan V: Effect of serum thyrotropin levels on the concentration of messenger RNA for thyroid peroxidase in the rat. Acta Endocrinol (Copenh). 1992 May;126(5):460-6. [PubMed:1320313 ]
Chiovato L, Pinchera A: The microsomal/peroxidase antigen: modulation of its expression in thyroid cells. Autoimmunity. 1991;10(4):319-31. [PubMed:1663395 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Details

1. Cytochrome P450 1A2

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:: CYP1A2
Uniprot ID:: P05177
Molecular Weight:: 58293.76 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Details

2. Cytochrome P450 2A6

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:: CYP2A6
Uniprot ID:: P11509
Molecular Weight:: 56501.005 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Details

3. Cytochrome P450 2B6

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:: CYP2B6
Uniprot ID:: P20813
Molecular Weight:: 56277.81 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Details

4. Cytochrome P450 2C19

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:: CYP2C19
Uniprot ID:: P33261
Molecular Weight:: 55930.545 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Details

5. Cytochrome P450 2C9

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:: CYP2C9
Uniprot ID:: P11712
Molecular Weight:: 55627.365 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Details

6. Cytochrome P450 2D6

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:: CYP2D6
Uniprot ID:: P10635
Molecular Weight:: 55768.94 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Details

7. Cytochrome P450 2E1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:: CYP2E1
Uniprot ID:: P05181
Molecular Weight:: 56848.42 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Details

8. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Vitamin d3 25-hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:: CYP3A4
Uniprot ID:: P08684
Molecular Weight:: 57342.67 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 16:52

Get DrugBank to go!

Structure for DB00763 (Methimazole)

Targets

References

Enzymes

References

References

References

References

References

References

References

References